|Mr. Douglas Arthur Doerfler||Founder, Pres, CEO & Exec. Director||705.25k||N/A||1956|
|Mr. Ronald Evan Holtz Ph.D., CPA||Sr. VP, Chief Accounting Officer, Company Sec. & Exec. Director||445.93k||N/A||1958|
|Ms. Amanda Louise Murphy C.F.A., CFA||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Maher Masoud||Exec. VP & Gen. Counsel||N/A||N/A||N/A|
|Mr. Thomas Michael Ross||Exec. VP of Global Sales||N/A||N/A||1961|
|Mr. Markus J. Hunkeler||VP of Marketing||N/A||N/A||N/A|
|Mr. Brad Calvin||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Claudio Dansky Ullmann M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Shruti Abbato||Exec. VP of Bus. Devel. for CARMA Cellular Therapies||N/A||N/A||N/A|
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
MaxCyte, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.